FDA Agreement on Mesoblast’s Use of Singapore Manufacturing Facility for MPCs Clinical Trial Production

News   May 21, 2013

 
FDA Agreement on Mesoblast’s Use of Singapore Manufacturing Facility for MPCs Clinical Trial Production
 
 
 
 

RELATED ARTICLES

Human Pluripotent Stem Cells Successfully 3D Printed

News

A breakthrough in the 3D-printing of human pluripotent stem cells means scientists are one step closer to being able to 3D print human organs and tissues for transplantation therapy.

READ MORE

Researchers Develop New Method to Generate Human Antibodies

News

Researchers hope their approach will help researchers rapidly generate therapeutic antibodies for the treatment of infectious diseases and other conditions such as cancer.

READ MORE

Large-Scale Production of Living Brain Cells Enables Entirely New Research

News

After performing a biopsy on the patient, the skin cells are transformed into brain cells that effectively imitate the disease and the age of the patient.

READ MORE

 

Comments | 0 ADD COMMENT

Like what you just read? You can find similar content on the communities below.

Cell Science Drug Discovery

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE